From Nasdaq:

Struggling basketball players might get replaced in the starting lineup, just like Tesla (NASDAQ: TSLA) is being challenged in the stock market. Tesla has lost over half its value and is below expectations, while Novo Nordisk (NYSE: NVO) is on the rise with impressive drug sales and promising clinical trial results. Tesla’s future looks dim compared to Novo Nordisk’s bright prospects.

Novo Nordisk’s market cap has surpassed Tesla’s, and its stock performance is outshining the electric vehicle maker. With successful drugs like Wegovy and Ozempic and promising clinical trial results for amycretin, Novo Nordisk is positioned for a strong future. Injecting new life into the Magnificent Seven stocks, Novo Nordisk should replace Tesla, and Eli Lilly (NYSE: LLY) should be added to the mix as well.

Investors are noticing Novo Nordisk’s potential, with its strong pipeline and solid drug sales. As Tesla struggles and Novo Nordisk shines, including Eli Lilly in the Magnificent Seven could be a wise move. Novo Nordisk’s bright future, steady stock performance, and impressive drug portfolio make it a top contender in the market. It’s time to rethink the Magnificent Seven and consider replacing Tesla with Novo Nordisk.

Before investing in Novo Nordisk, consider the top stock picks from the Motley Fool Stock Advisor team. Novo Nordisk might not be on their list, but the curated 10 best stocks hold promising returns. With expert guidance and regular updates, Stock Advisor has consistently outperformed the S&P 500. Take a closer look at the top stocks for potential growth opportunities.



Read more at Nasdaq: Forget Tesla: I Think This Stock Should Replace It in the “Magnificent Seven”